

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-248)

MIPASETAMAB UZOPTIRINE

PRONUNCIATION

mip" a set' a mab uz" op tir' een

THERAPEUTIC CLAIM

Treatment of solid tumors

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human receptor tyrosine kinase Axl) (human-Mus musculus monoclonal 1H12 γ 1-chain), disulfide with human-Mus musculus monoclonal 1H12 κ -chain, dimer, 302,302'-bis[N-[O-2-(acetylamino)-6-azido-2,6-dideoxy- β -D- galactopyranosyl-(1 \rightarrow 4)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 6)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-L- asparagine], click reaction product with N-[10,10-dioxido-1,12-dioxo-14-[(1 α ,8 α ,9 β)-bicyclo[6.1.0]non-4-yn-9-yl]-3,6,13-trioxa-10-thia-9,11-diazatetradec-1-yl]-L-valyl-N-[4-[[[(11S,11aS)-8-[[5-[[[(11aS)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]- 11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]oxy]methyl]phenyl]-L-alaninamide (Source: CAS)
2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* Tyrosine-protein kinase receptor UFO (AXL oncogene; EC=2.7.10.1)]; humanized monoclonal antibody conjugated to the pyrrolobenzodiazepine (PDB) dimer, SG3199; γ 1 heavy chain humanized (1-451) [VH humanized (*Homo sapiens* IGHV3-30*03 (93%) -(IGHD)-IGHJ4*01 (92%)] [8.8.15] (1-122) *Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(219)], CH3[K¹⁰⁷>del(452)]} (123-451)], (225-215')-disulfide with κ light chain humanized (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84%) -IGKJ4*01 (91%)] [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (231-231":234-234")-bisdisulfide, produced in Chinese CHO cells, glycoform alfa; conjugated on the two glycoengineered Asn-302 and Asn-302", via a spacer and cleavable valyl-alanyl linker, to the cytotoxic pyrrolobenzodiazepine (PBD) dimer, SG3199.

STRUCTURAL FORMULA

Heavy chains X & X''

QVQLVESGGG	VVQPGRSLRL	SCAASGFTFS	SYGMSWVRQA	PGKGLEWVAT	50
ISSGGSYTTY	PDSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYICARHP	100
IYYTYDDTMD	YWGQGTFTVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	200
QTYICNVNHNK	PSNTKVDKKV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	300
YNSTYRVVSV	LTVLHQDWLN	GKEYCKVSN	KALPAPIEKT	ISKAKGQPRE	350
PQVYTLPPSR	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTTP	400
PVLDSDGSFF	LYSKLTVDKS	RWQQGNVFSC	SVMHEALHNNH	YTQKSLSLSP	450
G					451


Light chains X' & X'''

EIVLTQSPGT	LSLSPGERAT	LSCSASSSVS	SGNFHWYQQK	PGLAPRLLIY	50'
RTSNLASGIP	ARFSGSGSGT	DFTLTISSE	PEDFAVYVCQ	QWSGYPWTFG	100'
GGTKLEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNMF	YPREAKVQWK	150'
VDNALQSGNS	QESVTEQDSK	DSTYLSSTL	TLSKADYEKH	KVYACEVTHQ	200'
GLSSPVTKSF	NRGEC				215'

Disulfide bridges location


22-96	22"-96"	23'-89'	23'''-89'''	135'-195'	135'''-195'''	149-205	149"-205"
215'-225	215'''-225'''	231-231"	234-234"	266-326	266'''-326'''	372-430	372"-430"

Chemically modified:



Q 1, 1" Pyroglutamyl :

Glycosylation sites : (N) :Asn-302 Asn-302"



MOLECULAR FORMULA	Not determined
MOLECULAR WEIGHT	Not determined
TRADEMARK	None as yet
SPONSOR	ADC Therapeutics
CODE DESIGNATIONS	ADCT-601
<u>CAS</u> REGISTRY NUMBER	2304799-73-1
UNII	71KV7F609O
WHO NUMBER	11416

gbk